Etelcalcetide is a calcimimetic peptide. It is filed in this library under bones & muscles, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Etelcalcetide has an FDA-approved product on the U.S. market, marketed as Parsabiv under application NDA208325.
The current label is held by Amgen, Inc.
From the FDA label
is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.Quoted from the FDA-approved prescribing information
The evidence
One source on Etelcalcetide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Etelcalcetide's FDA-approved label indicates it for a bone or parathyroid condition. These are the markers clinicians use when assessing calcium and bone turnover. They are listed here so you can read about them, not as a statement that Etelcalcetide changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Etelcalcetide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides